<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201008254548N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2010-11-13</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Transcutaneous Electrical Nerve Stimulation (TENS) and lidocaine spray on pain intensity during insertion of vascular needles in hemodialysis patients</public_title>
      <acronym>TENS</acronym>
      <scientific_title>The comparison of effect of Transcutaneous Electrical Nerve Stimulation (TENS) and lidocaine spray on pain intensity during insertion of vascular needles in hemodialysis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2010-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4851</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>chronic renal failure.</hc_freetext>
      <i_freetext>Intervention 1: Fourth intervention (TENS placebo): TENS is turned off and researcher place TENS electrodes with 6 centimeter distance from each other on the skin near the location of insertion of arterial needle. One minute after to place TENS electrodes on the skin, whereas TENS is turn off so, hemodialysis needle (gaoge 16) is inserted into vascular in fistula area by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse. Intervention 2: First intervention (TENS): TENS electrodes are placed on the skin with 6 centimeter distance from each other near the location of insertion of arterial needle by researcher. Then the TENS is turned on with frequency 100 Hz and pulse duration 0/1msec by researcher. One minute after using TENS, hemodialysis needle (gaoge 16) is inserted into vascular in fistula area by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse. Intervention 3: Second intervention (lidocaine placebo spray): Lidocaine placebo spray is water that is filled in emptied lidocaine spray bottle. 2 puffs are used from distance 5 centimeter on the skin in location of needle insertion by researcher. 5 minutes later, hemodialysis needle (gaoge 16) is inserted by dialysis ward nurse. Intervention 4: Third intervention (lidocaine spray): 2 puffs of lidocaine 10% spray (each puff include 10mg lidocaine) are used from distance 5 centimeter on the skin in location of insertion of arterial needle by researcher. 5 minute later, hemodialysis needle (gaoge 16) is inserted by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nahid Hoshmand Motlagh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Paramedicine Faculty, Semnan University Of Medical Sciences</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>35131038111</zip>
        <telephone>+98 32 1335 4191</telephone>
        <email>Hoshmand@sem-ums.ac.ir</email>
        <affiliation>Semnan University Of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Asgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Paramedicine Faculty, Semnan University Of Medical Sciences</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>35131038111</zip>
        <telephone>+98 23 1335 4191</telephone>
        <email>Asgari@Sem-Ums.ac.ir</email>
        <affiliation>Semnan University Of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: (1) The patient be alert, (2) The patient does not intake analgesic and narcotic drugs before 6 hours, (3) Not to have any pain in other parts of body, (4) Not to have internal cardiac pacemaker, (5) The patient must have arterio-venous fistula for veonous access.  Exclusion criteria: (1) To attend the study is completely optional, So the patient can avoid from study whenever he/she want, without any change in personnel’s behavior or care, (2) At the first action, if the patient 's vessels are not achievable , he/she is omitted from study, (3) patients who are in the low consciousness and cognition condition and could not answer the questions, (4) If the patient is transferred to other centers during studying.</inclusion_criteria>
      <agemin>10 years</agemin>
      <agemax>100 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N180</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>End-stage renal disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Fourth intervention (TENS placebo): TENS is turned off and researcher place TENS electrodes with 6 centimeter distance from each other on the skin near the location of insertion of arterial needle. One minute after to place TENS electrodes on the skin, whereas TENS is turn off so, hemodialysis needle (gaoge 16) is inserted into vascular in fistula area by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse.</i_keyword>
      <i_keyword>First intervention (TENS): TENS electrodes are placed on the skin with 6 centimeter distance from each other near the location of insertion of arterial needle by researcher. Then the TENS is turned on with frequency 100 Hz and pulse duration 0/1msec by researcher. One minute after using TENS, hemodialysis needle (gaoge 16) is inserted into vascular in fistula area by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse.</i_keyword>
      <i_keyword>Second intervention (lidocaine placebo spray): Lidocaine placebo spray is water that is filled in emptied lidocaine spray bottle. 2 puffs are used from distance 5 centimeter on the skin in location of needle insertion by researcher. 5 minutes later, hemodialysis needle (gaoge 16) is inserted by dialysis ward nurse.</i_keyword>
      <i_keyword>Third intervention (lidocaine spray): 2 puffs of lidocaine 10% spray (each puff include 10mg lidocaine) are used from distance 5 centimeter on the skin in location of insertion of arterial needle by researcher. 5 minute later, hemodialysis needle (gaoge 16) is inserted by dialysis ward nurse. One minute later, the pain severity is measured with Numeric Pain Intensity Scale by nurse.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity pain. Timepoint: One minute after entering the arterial needle. Method of measurement: Numeric Pain Intensity Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-08-24</approval_date>
        <contact_name>Semnan University of Medical Sciences</contact_name>
        <contact_address>Nursing and Paramedicine Faculty، Semnan University Of Medical Sciences Semnan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
